This often occurs in drug delivery patents. They try to find a small niche, but at the end of the day, that niche is unimportant clinically or otherwise. So, it is irrelevant if they can get to that size unless they demonstrate that it has real world utility. What is argued in a yet to be issued patent has no real import without such data. As an example, a company could patent a method for sequestering naltrexone, but as we all know, there are other patents that demonstrate the same thing. It is only a theoretical advantage to use one method over another until a direct comparison can be made.
News 
Market Data 
Discover 
AI
